Trijardy XR will be available in four different dosages and is indicated as a once-daily treatment, together with diet and exercise, for adults who are already on treatment for type 2 disease but require additional agents to attain healthy hemoglobin A1c targets, according to areleased by Eli Lilly, which will market the newly approved treatment together with Boehringer Ingelheim.
“Type 2 diabetes is a complex disease that often requires the use of multiple antidiabetic medications to improve glycemic control. Having three different diabetes medications in a single tablet is an important advance in diabetes treatment,”, professor and diabetes division chief at the University of Texas Health San Antonio, said in the release.
All three drugs are separately well-established therapies for type 2 diabetes.is the most commonly prescribed treatment for type 2. , a sodium-glucose transporter 2 inhibitor, and , a single-dose dipeptidyl peptidase–4 inhibitor, are approved for the reduction of blood sugar in patients with type 2 disease, and empagliflozin is also approved for lowering the risk of cardiovascular death in adults with type 2 and established cardiovascular disease, according to the statement. (In 2015, the FDA approved a combination of empagliflozin and linagliptin, , as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.)
The approval of the triple-combination treatment was based on findings from two randomized, open-label trials that assessed the bioequivalence of empagliflozin, linagliptin, and extended-release metformin hydrochloride fixed-dose combination tablets, as well as their individual components. In addition, the trials established that the safety profile of the combination therapy was similar to the safety profiles of the components, the statement said.
Lactic acidosis, pancreatitis, and heart failure are among the side effects associated with the combination therapy, with upper respiratory tract infection and gastroenteritis among the most common. Serious side effects include dehydration, ketoacidosis, kidney problems, urinary tract and vaginal yeast infections, and hypoglycemia.
As with empagliflozin and linagliptin alone, the combination therapy is not recommended for individuals with type 1 diabetes or diabetic ketoacidosis, and it has not been tested in patients with a history of pancreatitis. The combination also has a warning for lactic acidosis, a rare, but serious, condition that can arise with metformin accumulation.
The combination product is contraindicated for people with kidney problems and end-stage renal disease or who are on dialysis; have metabolic acidosis or diabetic ketoacidosis; or are allergic to empagliflozin, linagliptin, or metformin.